The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP

blonca9
Nov 20, 2024
1 min read

CEO Rajesh Devraj describes the company's focus on membrane protein function and normalizing it with small molecules, in this case for cholestasis and cholangitis associated with liver diseases.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight